Quantum Genomics
Biopharma developing cardiovascular treatments, now in judicial liquidation.
ALQGC | PA
Overview
Corporate Details
- ISIN(s):
- FR0010783837 (+4 more)
- LEI:
- 969500TFCD8K9RPM9K97
- Country:
- France
- Address:
- 6 RUE CAMBACERES, 75008 PARIS
- Website:
- https://quantum-genomics.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Quantum Genomics is a biopharmaceutical company focused on developing treatments for unmet medical needs, particularly in cardiovascular diseases such as hypertension and heart failure. The company's research was centered on a novel therapeutic approach involving Brain Aminopeptidase A Inhibition (BAPAI), with its lead drug candidate being firibastat. In early 2024, Quantum Genomics acquired the company Exactcure. However, recent developments indicate that the company has subsequently filed for judicial liquidation.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-06-13 18:00 |
Post-Annual General Meeting Information
Report de l'Assemblée Générale Mixte du 30/06/2025
|
French | 116.4 KB | ||
| 2025-04-30 20:00 |
Earnings Release
Quantum Genomics publishes its 2024 annual financial statements and announces a…
|
English | 206.5 KB | ||
| 2025-04-30 20:00 |
Delisting Announcement
Quantum Genomics publie ses comptes annuels 2024 et annonce un changement de li…
|
French | 254.0 KB | ||
| 2025-04-08 08:00 |
Delisting Announcement
Quantum Genomics fait un point sur sa situation
|
French | 688.8 KB | ||
| 2025-04-08 08:00 |
Delisting Announcement
Quantum Genomics provides an update on its situation
|
English | 626.0 KB | ||
| 2024-10-29 18:00 |
Earnings Release
Quantum Genomics publie ses résultats du 1er semestre 2024 et annonce la nomina…
|
French | 241.2 KB | ||
| 2024-09-27 08:00 |
Legal Proceedings Report
Quantum Genomics sécurise un financement avec le fonds Akkadian Partners Fund e…
|
French | 74.5 KB | ||
| 2024-09-04 18:00 |
Legal Proceedings Report
Quantum Genomics reviewed its financial situation and announced that it has fil…
|
English | 175.5 KB | ||
| 2024-09-04 18:00 |
Legal Proceedings Report
Quantum Genomics fait un point sur sa situation financière et annonce qu'elle a…
|
French | 150.0 KB | ||
| 2024-07-03 13:00 |
Capital/Financing Update
BILAN SEMESTRIEL S1 DU CONTRAT DE LIQUIDITE CONTRACTE AVEC LA SOCIETE DE BOURSE…
|
French | 275.3 KB | ||
| 2024-03-13 18:00 |
Business and Financial Review
Quantum Genomics publie ses résultats de l'exercice 2023. Le rapprochement avec…
|
French | 193.8 KB | ||
| 2024-03-13 18:00 |
Earnings Release
Quantum Genomics publishes its results for the 2023 financial year. The merger …
|
English | 166.3 KB | ||
| 2024-01-10 16:35 |
Capital/Financing Update
Bilan au 29 décembre 2023 du contrat de liquidité contracté avec la Société de …
|
English | 297.2 KB | ||
| 2024-01-10 16:30 |
Capital/Financing Update
Bilan au 29 décembre 2023 du contrat de liquidité contracté avec la Société de …
|
English | 297.2 KB | ||
| 2023-12-14 18:05 |
Regulatory News Service
Quantum Genomics enters into exclusive negotiations with ExactCure
|
English | 286.1 KB |
Automate Your Workflow. Get a real-time feed of all Quantum Genomics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Quantum Genomics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
